Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Merck,Australasian Leukaemia and Lymphoma Group (ALLG)
Scientific Title
An ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma